Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012032048
Ticker ROG.VX
Company ROCHE
Currency CHF
Price
Aware Investor Index (AII) 32.1194
Recommendation STRONG BUY
P/E 23.09
ROE 31.75 %
Capitalization 219,530,753,050 $
Dividend Yield 3.36 %
P/S 3.99
AII Position 65
P/E Position 340
ROE Position 83
Capitalization Position 28
Dividend Yield Position 211
Sales 53,299,000,000 CHF
10-Year Average Earnings 9,210,600,000 CHF
Shares Outstanding 860,000,000
Equity 29,007,000,000 CHF
Dividend per Share 8.3 CHF
Industry Pharmaceutical
Country Switzerland
ROCHE Investor Relations Web Site http://www.roche.com/investors.htm







Sales:

YEAR MONTH AMOUNT
2017 12 53,299,000,000.00 CHF
2016 12 50,576,000,000.00 CHF
2015 12 48,145,000,000.00 CHF
2014 12 47,462,000,000.00 CHF
2013 12 46,780,000,000.00 CHF

Earnings:

YEAR MONTH AMOUNT
2017 12 8,825,000,000.00 CHF
2016 12 9,733,000,000.00 CHF
2015 12 8,863,000,000.00 CHF
2014 12 9,332,000,000.00 CHF
2013 12 11,164,000,000.00 CHF
2012 12 9,427,000,000.00 CHF
2011 12 9,343,000,000.00 CHF
2010 12 8,666,000,000.00 CHF
2009 12 7,784,000,000.00 CHF
2008 12 8,969,000,000.00 CHF

Equity:

YEAR MONTH AMOUNT
2017 12 29,007,000,000.00 CHF
2016 12 26,402,000,000.00 CHF
2015 12 23,300,000,000.00 CHF
2014 12 21,558,000,000.00 CHF
2013 12 21,241,000,000.00 CHF
2012 12 16,728,000,000.00 CHF
2011 12 14,482,000,000.00 CHF

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 860,000,000
2016 12 860,000,000
2015 12 862,000,000
2014 12 863,000,000
2013 12 863,000,000
2012 12 848,000,000
2011 12 849,000,000

 












Bloomberg News for ROCHE:



Google News for ROCHE:

CNBC - 26 Jul 2018
Roche raises outlook for 2018 as new drugs gain traction
Swiss drugmaker Roche lifted its 2018 outlook on Thursday for the second time this year, after first-half sales and profit easily beat analyst ...
Reuters - 21 Nov 2018
Roche-AbbVie cancer drug gets accelerated FDA approval
(Reuters) - Roche Holding AG said on Wednesday its cancer drug, Venclexta, received accelerated approval from the U.S. Food and Drug ...
Business Insider - 3 Dec 2018
Roche says Hemlibra effective in pivotal study
ZURICH (Reuters) - Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of ...
MarketWatch - 10 Dec 2018
Roche taps Genentech head for pharma division
Roche Holding AG on Monday appointed Bill Anderson, head of its Genentech unit, to lead the company's broader pharmaceuticals business, ...
Wall Street Journal - 9 Dec 2018
Roche Executive Daniel O'Day Is Named Gilead CEO
Mr. O'Day, whose hiring was announced early Monday, will become Gilead CEO after a long career at Switzerland's Roche Holding AG ...
Forbes - 11 Dec 2017
Roche's Fight With Pfizer May Be Just The Beginning
Roche recently sued Pfizer to block the latter's biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in ...
Reuters - 2 Feb 2016
Roche eyes acquisition of Pacific Biosciences: sources
(Reuters) - Roche Holding AG ROG.VX has in recent weeks approached Pacific Biosciences of California Inc (PACB.O) to discuss acquiring the ...
Investopedia - 22 Dec 2015
The Top 10 Biotechnology Companies (JNJ, ROG.VX)
Founded in Switzerland in 1896, Roche (NASDAQ: ROG.VX) calls itself the largest biotech company in the world, with 17 biopharmaceuticals ...
Investopedia - 17 Mar 2017
Roche Restructuring Shows Trouble in US Diabetes Biz (RHHBY)
Amid increasing competition in the U.S. diabetes care market, Roche AG (RHHBY) plans to restructure its U.S. operations and reduce ...
Seeking Alpha - 1 May 2017
Morningstar: This Large Biotech Could Be The World's Best Stock
Roche, the Swiss biotech and lab diagnostics giant, reported a strong but unremarkable Q1 recently. A mainstream stock analytic house, ...


Back